无并发症恶性疟延迟治疗进展为重症疟疾的影响:系统综述与汇总多中心个体患者荟萃分析
研究汇总13项研究共3989例重症疟疾和5780例无并发症疟疾病例的个体数据,采用年龄校正混合效应回归分析治疗延迟与重症疟疾的关联。结果显示,儿童症状出现至就诊延迟>24小时与任何重症表型风险升高相关(OR=1.33,95%CI:1.07-1.64,p=0.009)。延迟2-3天和>7天与儿童重症疟性贫血风险显著增加相关(OR分别为2.79和5.46)。若所有患者在症状出现首日获得治疗,估计可避免42.8%的儿童和48.5%的成人重症疟性贫血病例。
要点
- 儿童症状出现至就诊延迟>24小时与重症疟疾风险升高相关(OR=1.33)。
- 延迟2-3天和>7天与儿童重症疟性贫血风险显著增加相关(OR分别为2.79和5.46)。
- 首日治疗可避免约42.8%儿童和48.5%成人重症疟性贫血病例。
核心结论
- 快速获得治疗与降低重症疟疾风险相关,尤其对重症疟性贫血关联最强。
- 及时治疗也可能预防其他重症表型,但关联较弱,可能受选择偏倚、样本量或病理差异影响。
- 研究结果有助于评估改善治疗可及性干预措施的影响。
研究设计与样本
- 系统综述与汇总多中心个体患者荟萃分析,检索Ovid MEDLINE和Embase至2017年9月22日。
- 纳入13项研究(5项病例对照和8项其他观察性临床研究),共3989例重症疟疾患者(94.1%年龄<15岁)和5780例无并发症疟疾病例(79.6%年龄<15岁)。
- 研究地点包括贝宁、马来西亚、莫桑比克、坦桑尼亚、冈比亚、乌干达、也门和赞比亚。
- 使用Newcastle-Ottawa量表评估偏倚风险,所有研究评分≥7/10,评为「良好」。
- 采用年龄校正混合效应回归比较无并发症与不同重症表型患者的治疗延迟。
主要发现
- 儿童症状出现至就诊延迟>24小时与任何重症表型风险升高显著相关(OR=1.33,95%CI:1.07-1.64,p=0.009)。
- 儿童报告疾病持续时间是重症疟性贫血的强预测因素:延迟2-3天OR=2.79(95%CI:1.92-4.06,p<0.001),延迟>7天OR=5.46(95%CI:3.49-8.53,p<0.001),均与症状出现24小时内治疗相比。
- 若所有患者在症状出现首日获得治疗且关联完全因果,估计可避免研究地区42.8%的儿童和48.5%的成人重症疟性贫血病例。
- 在专门记录非重症症状起病的研究中,长治疗延迟与其他重症表型中度相关:脑型疟疾(延迟>3至≤4天 vs ≤24小时)OR=2.42(95%CI:1.24-4.72,p=0.01);呼吸窘迫综合征OR=4.09(95%CI:1.70-9.82,p=0.002)。
临床怎么用
- 强调疑似疟疾患者应在症状出现24小时内尽快获得治疗,以降低重症风险,尤其儿童重症疟性贫血。
- 支持社区健康工作者实施的「检测和治疗」等改善治疗可及性干预措施,以缩短治疗延迟。
- 研究结果可用于量化及时治疗对减少重症疟疾负担的潜在影响。
局限性
- 观察性研究普遍存在未测量的混杂因素。
- 许多重症病例和死亡发生在流行国家的医疗机构外,延迟或无治疗的效果难以量化。
- 其他重症表型的关联可能受选择偏倚或样本量问题影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delay in receiving treatment for uncomplicated malaria (UM) is often reported to increase the risk of developing severe malaria (SM), but access to treatment remains low in most high-burden areas. Understanding the contribution of treatment delay on progression to severe disease is critical to determine how quickly patients need to receive treatment and to quantify the impact of widely implemented treatment interventions, such as 'test-and-treat' policies administered by community health workers (CHWs). We conducted a pooled individual-participant meta-analysis to estimate the association between treatment delay and presenting with SM. METHODS AND FINDINGS: A search using Ovid MEDLINE and Embase was initially conducted to identify studies on severe Plasmodium falciparum malaria that included information on treatment delay, such as fever duration (inception to 22nd September 2017). Studies identified included 5 case-control and 8 other observational clinical studies of SM and UM cases. Risk of bias was assessed using the Newcastle-Ottawa scale, and all studies were ranked as 'Good', scoring ≥7/10. Individual-patient data (IPD) were pooled from 13 studies of 3,989 (94.1% aged <15 years) SM patients and 5,780 (79.6% aged <15 years) UM cases in Benin, Malaysia, Mozambique, Tanzania, The Gambia, Uganda, Yemen, and Zambia. Definitions of SM were standardised across studies to compare treatment delay in patients with UM and different SM phenotypes using age-adjusted mixed-effects regression. The odds of any SM phenotype were significantly higher in children with longer delays between initial symptoms and arrival at the health facility (odds ratio [OR] = 1.33, 95% CI: 1.07-1.64 for a delay of >24 hours versus ≤24 hours; p = 0.009). Reported illness duration was a strong predictor of presenting with severe malarial anaemia (SMA) in children, with an OR of 2.79 (95% CI:1.92-4.06; p < 0.001) for a delay of 2-3 days and 5.46 (95% CI: 3.49-8.53; p < 0.001) for a delay of >7 days, compared with receiving treatment within 24 hours from symptom onset. We estimate that 42.8% of childhood SMA cases and 48.5% of adult SMA cases in the study areas would have been averted if all individuals were able to access treatment within the first day of symptom onset, if the association is fully causal. In studies specifically recording onset of nonsevere symptoms, long treatment delay was moderately associated with other SM phenotypes (OR [95% CI] >3 to ≤4 days versus ≤24 hours: cerebral malaria [CM] = 2.42 [1.24-4.72], p = 0.01; respiratory distress syndrome [RDS] = 4.09 [1.70-9.82], p = 0.002). In addition to unmeasured confounding, which is commonly present in observational studies, a key limitation is that many severe cases and deaths occur outside healthcare facilities in endemic countries, where the effect of delayed or no treatment is difficult to quantify. CONCLUSIONS: Our results quantify the relationship between rapid access to treatment and reduced risk of severe disease, which was particularly strong for SMA. There was some evidence to suggest that progression to other severe phenotypes may also be prevented by prompt treatment, though the association was not as strong, which may be explained by potential selection bias, sample size issues, or a difference in underlying pathology. These findings may help assess the impact of interventions that improve access to treatment.
引用
- Mousa A, Al-Taiar A, Anstey NM, et al. The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysis. PLoS Med. 2020. PMID: 33075101. doi:10.1371/journal.pmed.1003359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。